Department of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
J Invest Dermatol. 2011 Sep;131(9):1817-20. doi: 10.1038/jid.2011.147. Epub 2011 May 19.
The recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has been lauded as a success story for personalized cancer therapy since short-term clinical responses were observed in the majority of patients. However, initial responses were followed by subsequent tumor re-growth, and a subset of patients showed intrinsic resistance. Bi-directional translational efforts are now essential to determine the mechanisms underlying acquired/secondary and intrinsic resistance to RAF inhibitors.
最近，PLX4032/RG7204 联合 RAF 抑制剂在晚期突变型 B-RAF 黑色素瘤患者中的临床试验取得了成功，这被认为是癌症个体化治疗的一个成功案例，因为大多数患者观察到了短期的临床反应。然而，最初的反应后是随后的肿瘤复发，并且一部分患者表现出内在的耐药性。现在，双向转化研究对于确定获得性/继发性和内在性 RAF 抑制剂耐药的机制至关重要。
